Brief: Advaxis Says Received Notice That It Is Not In Compliance With Nasdaq Listing Rule
April 10 (Reuters) - Advaxis Inc ADXS.O :
* ADVAXIS - RECEIVED WRITTEN NOTICE NASDAQ STOCK MARKET
INDICATING
THAT ADVAXIS WAS NOT IN COMPLIANCE WITH NASDAQ LISTING RULE
* ADVAXIS INC - CURRENTLY MONITORING CLOSING BID PRICE OF
ITS
COMMON STOCK AND EVALUATING ITS ALTERNATIVES
Source text: https://bit.ly/2Ve7wdi
Further company coverage: ADXS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ayala Pharmaceuticals
See all newsBrief: Ayala Pharmaceuticals Completes Sale Of AL102 To Immunome
Immunome slides on $200 mln equity offering
Immunome edges up after $200 mln equity offering
Brief: Immunome To Acquire AL102 Phase 3 Asset for the Treatment of Desmoid Tumors From Ayala Pharmaceuticals
Brief: Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors